Lipocine price target lowered to $6.75 from $10 at Alliance Global Partners

Alliance Global Partners lowered the firm’s price target on Lipocine (LPCN) to $6.75 from $10 and keeps a Buy rating on the shares after the company reported Q4 earnings that the firm says “were optically strong but fundamentally as expected.” The firm’s reduced target reflects LPCN 1154 delays after the company said LPCN 1154 has been delayed by about two years due to requirements for a safety/efficacy trial, the analyst noted.